ClinicalTrials.gg
Not yet recruitingNCT07001098AKIUpdated Jun 3, 2025

Amino Acids for Cardiac Surgery Associated AKI

A Phase 2 interventional study of Amino Acids and Placebo in Acute Kidney Injury, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Stanford University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
164th of 237
30 · median 67
Started
2025
with 21 others
Phase 2
54 of 370
11 open now
Primary completion
2026-11
later than 19 of 87 live
Registered
340th of 370
by date
Lead sponsor
6 of 370
Stanford University

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 164th largest by planned enrollment of the 237 interventional ones that give a count, is one of 22 that started in 2025, is one of 54 in phase 2, reaches primary completion later than 19 of the 87 other live ones, and was the 340th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the feasibility of amino acid infusions in pediatric cardiac surgery patients.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • cardiac surgery
04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing cardiac surgery and expected to be high risk

Exclusion criteria

Exclusion Criteria:

  • preoperative extracorporeal organ support
  • CKD history (\<60ml/min/1.73m2 [≤1year] and GFR\<90ml/min/1.73m2 [>1 year])
  • serum creatinine defined preoperative AKI.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Amino acid

    Participants receive amino acids for up to 3 days starting at the time of their cardiac surgery

    Drug: Amino Acids

  • Placebo comparator
    Placebo

    Participants receive equivalent volume of placebo for up to 3 days starting at the time of their cardiac surgery

    Drug: Placebo

Interventions

  • The participants receive a continuous infusion of a balanced mixture of amino acids (Trophamine) in a dose of 2g/kg/day (max 100g/day) starting at the time of cardiac surgery up to 3 days

    Also known as: AA, Trophamine

  • DrugPlacebo

    The participants receive a continuous infusion of a lactated ringers (placebo), equivalent volume to amino acids, starting at the time of cardiac surgery up to 3 days

    Also known as: Lactated Ringer

06

What researchers measure

Primary outcomes

  1. Number of Participants with Amino acids Related Adverse Events

    Time frame: Baseline, Daily during infusion upto 48 hours after completion of infusion (upto 5 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Nov 2026, 14 months later.

Of 39 non-industry phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 14 months is below that.

Counting every sponsor, half of 57 studies reached it within 29 months; a quarter within 16 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 3, 2025
StartEst.
Sep 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07001098
Responsible party
Shina Menon (Associate Professor, Pediatrics, Stanford University) — Principal investigator
First posted
Jun 3, 2025
Start date
Sep 2025 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jun 3, 2025

Study contacts

Shina Menon, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amino Acids

Start the discussion